14. Referanser

Adam, M. A., Pura, J., Gu, L., Dinan, M. A., Tyler, D. S., Reed, S. D., Scheri, R., Roman, S. A., & Sosa, J. A. (2014). Extent of surgery for papillary thyroid cancer is not associated with survival: an analysis of 61,775 patients. Annals of Surgery, 260(4), 601-5; discussion 605-7.

Ali, S. Z., Baloch, Z. W., Cochand-Priollet, B., Schmitt, F. C., Vielh, P., & VanderLaan, P. A. (2023). The 2023 Bethesda System for Reporting Thyroid Cytopathology. Thyroid, 33(9), 1039-1044.

Ali, S. Z., VanderLaan, P. A. (2023). The Bethesda System for Reporting Thyroid Cytopathology: Definitions, Criteria, and Explanatory Notes. Springer International Publishing AG.

Altaraihi, M., Hansen, T. V. O., Santoni-Rugiu, E., Rossing, M., Rasmussen Å, K., Gerdes, A. M., & Wadt, K. (2021). Prevalence of Pathogenic Germline DICER1 Variants in Young Individuals Thyroidectomised Due to Goitre - A National Danish Cohort. Frontiers in Endocrinology, 12, 727970.

Atkins, F., Van Nostrand, D., Moreau, S., Burman, K., & Wartofsky, L. (2015). Validation of a Simple Thyroid Cancer Dosimetry Model Based on the Fractional Whole-Body Retention at 48 Hours Post-Administration of (131)I. Thyroid, 25(12), 1347-50.

Baloch, Z. W., Asa, S. L., Barletta, J. A., Ghossein, R. A., Juhlin, C. C., Jung, C. K., LiVolsi, V. A., Papotti, M. G., ... Mete, O. (2022). Overview of the 2022 WHO Classification of Thyroid Neoplasms. Endocrine Pathology, 33(1), 27-63.

Barczyński, M., Konturek, A., Stopa, M., & Nowak, W. (2013). Prophylactic central neck dissection for papillary thyroid cancer. The British journal of surgery, 100(3), 410-8.

Beheshti, M., Pöcher, S., Vali, R., Waldenberger, P., Broinger, G., Nader, M., Kohlfürst, S., Pirich, C., ... Langsteger, W. (2009). The value of 18F-DOPA PET-CT in patients with medullary thyroid carcinoma: comparison with 18F-FDG PET-CT. European Radiology, 19(6), 1425-34.

Benua, R. S., Cicale, N. R., Sonenberg, M., & Rawson, R. W. (1962). The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. American journal of roentgenology, radium therapy, and nuclear medicine, 87, 171-82.

Bergenfelz, A., Barczynski, M., Heie, A., Muth, A., Passler, C., Schneider, M., Wierzbicka, P., Konturek, A., ... Hermann, M. (2023). Impact of autofluorescence for detection of parathyroid glands during thyroidectomy on postoperative parathyroid hormone levels: parallel multicentre randomized clinical trial. British Journal of Surgery, 110(12), 1824-1833.

Bible, K. C., Kebebew, E., Brierley, J., Brito, J. P., Cabanillas, M. E., Clark, T. J. ,. J., Di Cristofano, A., Foote, R., ... Wong-Clark, C. K. (2021). 2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer. Thyroid, 31(3), 337-386.

Bilimoria, K. Y., Bentrem, D. J., Linn, J. G., Freel, A., Yeh, J. J., Stewart, A. K., Winchester, D. P., Ko, C. Y., ... Sturgeon, C. (2007). Utilization of total thyroidectomy for papillary thyroid cancer in the United States. Surgery, 142(6), 906-13; discussion 913.e1-2.

Bisof, V., Rakusic, Z., & Despot, M. (2015). Treatment of patients with anaplastic thyroid cancer during the last 20 years: whether any progress has been made?. European Archives of Oto-Rhino-Laryngology, 272(7), 1553-67.

Brauckhoff, M. (2014). Classification of aerodigestive tract invasion from thyroid cancer. Langenbeck's archives of surgery, 399(2), 209-16.

Brauckhoff, M., Gimm, O., Weiss, C. L., Ukkat, J., Sekulla, C., Brauckhoff, K., Thanh, P. N., & Dralle, H. (2004). Multiple endocrine neoplasia 2B syndrome due to codon 918 mutation: clinical manifestation and course in early and late onset disease. World Journal of Surgery, 28(12), 1305-11.

Brierley, J. D. ,., Gospodarowicz, M. K., Wittekind, C. (2017). TNM classification of malignant tumors. John Wiley & Sons, Inc.

Brose, M. S., Cabanillas, M. E., Cohen, E. E., Wirth, L. J., Riehl, T., Yue, H., Sherman, S. I., & Sherman, E. J. (2016). Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial. The Lancet. Oncology, 17(9), 1272-82.

Brose, M. S., Nutting, C. M., Jarzab, B., Elisei, R., Siena, S., Bastholt, L., de la Fouchardiere, C., Pacini, F., ... Schlumberger, M. J. (2014). Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet, 384(9940), 319-28.

Brose, M. S., Robinson, B., Sherman, S. I., Krajewska, J., Lin, C. C., Vaisman, F., Hoff, A. O., Hitre, E., ... Capdevila, J. (2021). Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. Oncology, 22(8), 1126-1138.

Brouwer, C. L., Steenbakkers, R. J., Bourhis, J., Budach, W., Grau, C., Grégoire, V., van Herk, M., Lee, A., ... Langendijk, J. A. (2015). CT-based delineation of organs at risk in the head and neck region: DAHANCA, EORTC, GORTEC, HKNPCSG, NCIC CTG, NCRI, NRG Oncology and TROG consensus guidelines. Radiotherapy and Oncology, 117(1), 83-90.

Bümming, P., Ahlman, H., Nilsson, B., Nilsson, O., Wängberg, B., & Jansson, S. (2008). Can the early reduction of tumour markers predict outcome in surgically treated sporadic medullary thyroid carcinoma?. Langenbeck's archives of surgery, 393(5), 699-703.

Capdevila, J., Wirth, L. J., Ernst, T., Ponce Aix, S., Lin, C. C., Ramlau, R., Butler, M. O., Delord, J. P., ... Taylor, M. (2020). PD-1 Blockade in Anaplastic Thyroid Carcinoma. Journal of Clinical Oncology, 38(23), 2620-2627.

Capezzone, M., Robenshtok, E., Cantara, S., & Castagna, M. G. (2021). Familial non-medullary thyroid cancer: a critical review. Journal of Endocrinological Investigation, 44(5), 943-950.

Carhill, A. A., Litofsky, D. R., Ross, D. S., Jonklaas, J., Cooper, D. S., Brierley, J. D., Ladenson, P. W., Ain, K. B., ... Sherman, S. I. (2015). Long-Term Outcomes Following Therapy in Differentiated Thyroid Carcinoma: NTCTCS Registry Analysis 1987-2012. Journal of Clinical Endocrinology and Metabolism, 100(9), 3270-9.

Chernock, R. D., & Hagemann, I. S. (2015). Molecular pathology of hereditary and sporadic medullary thyroid carcinomas. American Journal of Clinical Pathology, 143(6), 768-77.

Cho, J. W., Park, J. H., Lee, Y. M., Hong, S. J., & Yoon, J. H. (2019). Comparison of short-term oncologic outcome of robotic thyroid surgery using dynamic risk stratification: A propensity score-matched comparison study. Surgery, 165(3), 608-616.

Contrera, K. J., Gule-Monroe, M. K., Hu, M. I., Cabanillas, M. E., Busaidy, N. L., Dadu, R., Waguespack, S. G., Wang, J. R., ... Zafereo, M. E. (2023). Neoadjuvant Selective RET Inhibitor for Medullary Thyroid Cancer: A Case Series. Thyroid, 33(1), 129-132.

Council of the European Union (2014). Laying down basic safety standards for protection against the dangers arising from exposure to ionising radiation, and repealing Directives 89/618/Euratom, 90/641/Euratom, 96/29/Euratom, 97/43/Euratom and 2003/122/Euratom Official Journal of the European Union L 13/1: Hentet fra https://eur-lex.europa.eu/eli/dir/2013/59/oj

Dadgar, H., Jafari, E., Ahmadzadehfar, H., Rekabpour, S. J., Ravanbod, M. R., Kalantarhormozi, M., Nabipour, I., & Assadi, M. (2023). Feasibility and therapeutic potential of the 68Ga/177Lu-DOTATATE theranostic pair in patients with metastatic medullary thyroid carcinoma. Annales d'Endocrinologie, 84(1), 45-51.

DAHANCA, Regionernes Kliniske Kvalitetsudviklingsprogram (2022). Behandling af thyroideacancer Version 1.0 [s.l.]: DAHANCA og Regionernes Kliniske Kvalitetsudviklingsprogram. Hentet fra https://www.dahanca.dk/uploads/TilFagfolk/Guideline/FORMS2005_Behandling_DATHYRCA_2022.pdf.pdf

Dehbi, H. M., Mallick, U., Wadsley, J., Newbold, K., Harmer, C., & Hackshaw, A. (2019). Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial. The lancet. Diabetes & endocrinology, 7(1), 44-51.

Den norske legeforening (2012). Veileder i biopsibesvarelse av maligne svulster (2 utg.) Oslo: Legeforeningen. Hentet fra https://www.legeforeningen.no/contentassets/f41faaaac3cf410a969ed5eaa7418358/veileder-i-biopsiibesvarelse-av-malingne-svulster.pdf

Deniwar, A., Hammad, A. Y., Ali, D. B., Alsaleh, N., Lahlouh, M., Sholl, A. B., Moroz, K., Aslam, R., ... Kandil, E. (2017). Optimal timing for a repeat fine-needle aspiration biopsy of thyroid nodule following an initial nondiagnostic fine-needle aspiration. American Journal of Surgery, 213(2), 433-437.

Dierks, C., Seufert, J., Aumann, K., Ruf, J., Klein, C., Kiefer, S., Rassner, M., Boerries, M., ... Thomusch, O. (2021). Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma. Thyroid, 31(7), 1076-1085.

Doebele, R. C., Drilon, A., Paz-Ares, L., Siena, S., Shaw, A. T., Farago, A. F., Blakely, C. M., Seto, T., ... Demetri, G. D. (2020). Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. The Lancet. Oncology, 21(2), 271-282.

Donis-Keller, H., Dou, S., Chi, D., Carlson, K. M., Toshima, K., Lairmore, T. C., Howe, J. R., Moley, J. F., ... Wells, S. A. ,. J. (1993). Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Human Molecular Genetics, 2(7), 851-6.

Dorn, R., Kopp, J., Vogt, H., Heidenreich, P., Carroll, R. G., & Gulec, S. A. (2003). Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk-adapted approach. Journal of Nuclear Medicine, 44(3), 451-6.

Dralle, H., Weber, F., Machens, A., Brandenburg, T., Schmid, K. W., & Führer-Sakel, D. (2023). Hemithyreoidektomie oder totale Thyreoidektomie beim papillären Niedrigrisikokarzinom der Schilddrüse? : Chirurgische Kriterien der primären und sekundären Therapiewahl im interdisziplinären Behandlungskonzept. Chirurgie (Heidelberg, Germany), 94(1), 79-92.

Drilon, A., Laetsch, T. W., Kummar, S., DuBois, S. G., Lassen, U. N., Demetri, G. D., Nathenson, M., Doebele, R. C., ... Hyman, D. M. (2018). Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. New England Journal of Medicine, 378(8), 731-739.

Durski, J. M., Hruska, C. B., Bogsrud, T. V., Ryder, M., & Johnson, G. B. (2021). 123I Scan With Whole-Body Retention Measurement at 48 Hours for Simplified Dosimetry Before 131I Treatment of Metastatic Thyroid Cancer. Clinical Nuclear Medicine, 46(3), e151-e153.

Eckelt, F., Vogel, M., Geserick, M., Kirsten, T., Bae, Y. J., Baber, R., Schaab, M., Thiery, J., ... Kratzsch, J. (2019). Calcitonin measurement in pediatrics: reference ranges are gender-dependent, validation in medullary thyroid cancer and thyroid diseases. Clinical Chemistry and Laboratory Medicine, 57(8), 1242-1250.

Elisei, R., Schlumberger, M. J., Müller, S. P., Schöffski, P., Brose, M. S., Shah, M. H., Licitra, L., Jarzab, B., ... Sherman, S. I. (2013). Cabozantinib in progressive medullary thyroid cancer. Journal of Clinical Oncology, 31(29), 3639-46.

Eng, C., Smith, D. P., Mulligan, L. M., Nagai, M. A., Healey, C. S., Ponder, M. A., Gardner, E., Scheumann, G. F., ... et al. (1994). Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours. Human Molecular Genetics, 3(2), 237-41.

Farhat, N. A., Faquin, W. C., & Sadow, P. M. (2013). Primary mucoepidermoid carcinoma of the thyroid gland: a report of three cases and review of the literature. Endocrine Pathology, 24(4), 229-33.

Filetti, S., Durante, C., Hartl, D., Leboulleux, S., Locati, L. D., Newbold, K., Papotti, M. G., & Berruti, A. (2019). Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Annals of Oncology, 30(12), 1856-1883.

Francis, G. L., Waguespack, S. G., Bauer, A. J., Angelos, P., Benvenga, S., Cerutti, J. M., Dinauer, C. A., Hamilton, J., ... Yamashita, S. (2015). Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid, 25(7), 716-59.

Frank-Raue, K., Schott, M., & Raue, F. (2018). Empfehlung zum Calcitonin-Screening bei Struma nodosa. [Recommendation for Calcitonin Screening in Nodular Goiter]. Deutsche Medizinische Wochenschrift, 143(15), 1065-1069 [På tysk].

Frich, P. S., Sigstad, E., Berstad, A. E., Fagerlid, K. H., Paulsen, T. H., Bjøro, T., & Flinder, L. I. (2022). Long-Term Efficacy of Ethanol Ablation as Treatment of Metastatic Lymph Nodes From Papillary Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 107(5), e2141-e2147.

Fugazzola, L., Pinchera, A., Luchetti, F., Iacconi, P., Miccoli, P., Romei, C., Puccini, M., & Pacini, F. (1994). Disappearance rate of serum calcitonin after total thyroidectomy for medullary thyroid carcinoma. International Journal of Biological Markers, 9(1), 21-4.

Grégoire, V., Ang, K., Budach, W., Grau, C., Hamoir, M., Langendijk, J. A., Lee, A., Le, Q. T., ... Lengele, B. (2014). Delineation of the neck node levels for head and neck tumors: a 2013 update. DAHANCA, EORTC, HKNPCSG, NCIC CTG, NCRI, RTOG, TROG consensus guidelines. Radiotherapy and Oncology, 110(1), 172-81.

Grégoire, V., Evans, M., Le, Q. T., Bourhis, J., Budach, V., Chen, A., Eisbruch, A., Feng, M., ... Grau, C. (2018). Delineation of the primary tumour Clinical Target Volumes (CTV-P) in laryngeal, hypopharyngeal, oropharyngeal and oral cavity squamous cell carcinoma: AIRO, CACA, DAHANCA, EORTC, GEORCC, GORTEC, HKNPCSG, HNCIG, IAG-KHT, LPRHHT, NCIC CTG, NCRI, NRG Oncology, PHNS, SBRT, SOMERA, SRO, SSHNO, TROG consensus guidelines. Radiotherapy and Oncology, 126(1), 3-24.

Gustave Roussy (2013-2030). Differentiated Thyroid Cancer: is There a Need for Radioiodine Ablation in Low Risk Patients? (ESTIMABL2) [pågående studie]. (NCT01837745). Hentet fra https://clinicaltrials.gov/study/NCT01837745

Guth, S., Theune, U., Aberle, J., Galach, A., & Bamberger, C. M. (2009). Very high prevalence of thyroid nodules detected by high frequency (13 MHz) ultrasound examination. European Journal of Clinical Investigation, 39(8), 699-706.

Hadoux, J., Elisei, R., Brose, M. S., Hoff, A. O., Robinson, B. G., Gao, M., Jarzab, B., Isaev, P., ... Wirth, L. J. (2023). Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer. New England Journal of Medicine, 389(20), 1851-1861.

Han, M., & Fan, F. (2023). Bethesda System for Reporting Thyroid Cytopathology–An Updated Review. Journal of Clinical and Translational Pathology, 3(2), 84-98.

Haugen, B. R., Alexander, E. K., Bible, K. C., Doherty, G. M., Mandel, S. J., Nikiforov, Y. E., Pacini, F., Randolph, G. W., ... Wartofsky, L. (2016). 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid, 26(1), 1-133.

Hay, I. D., Gonzalez-Losada, T., Reinalda, M. S., Honetschlager, J. A., Richards, M. L., & Thompson, G. B. (2010). Long-term outcome in 215 children and adolescents with papillary thyroid cancer treated during 1940 through 2008. World Journal of Surgery, 34(6), 1192-202.

Hay, I. D., Lee, R. A., & Charboneau, J. W. (2022). Efficacy of Ethanol Ablation in Long-Term Local Control of Neck Nodal Metastases in Adult Papillary Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 107(6), e2636-e2637.

Heilo, A., Sigstad, E., Fagerlid, K. H., Håskjold, O. I., Grøholt, K. K., Berner, A., Bjøro, T., & Jørgensen, L. H. (2011). Efficacy of ultrasound-guided percutaneous ethanol injection treatment in patients with a limited number of metastatic cervical lymph nodes from papillary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism, 96(9), 2750-5.

Higashiyama, T., Ito, Y., Hirokawa, M., Fukushima, M., Uruno, T., Miya, A., Matsuzuka, F., & Miyauchi, A. (2010). Induction chemotherapy with weekly paclitaxel administration for anaplastic thyroid carcinoma. Thyroid, 20(1), 7-14.

Hirsch, D., Twito, O., Levy, S., Bachar, G., Robenshtok, E., Gross, D. J., Mazeh, H., Benbassat, C., & Grozinsky-Glasberg, S. (2018). Temporal Trends in the Presentation, Treatment, and Outcome of Medullary Thyroid Carcinoma: An Israeli Multicenter Study. Thyroid, 28(3), 369-376.

Hoang, J. K., Langer, J. E., Middleton, W. D., Wu, C. C., Hammers, L. W., Cronan, J. J., Tessler, F. N., Grant, E. G., & Berland, L. L. (2015). Managing incidental thyroid nodules detected on imaging: white paper of the ACR Incidental Thyroid Findings Committee. Journal of the American College of Radiology : JACR, 12(2), 143-50.

Hocevar, M., Auersperg, M., & Stanovnik, L. (1997). The dynamics of serum thyroglobulin elimination from the body after thyroid surgery. European Journal of Surgical Oncology, 23(3), 208-10.

Hoda, R. S., Rao, R., Scognamiglio, T. (2020). Atlas of Thyroid Cytopathology on Liquid-Based Preparations: Correlation with Clinical, Radiological, Molecular Tests and Histopathology. Springer International Publishing AG.

Hong, C. M., Son, S. H., Kim, C. Y., Kim, D. H., Jeong, S. Y., Lee, S. W., Lee, J., & Ahn, B. C. (2014). Emptying effect of massage on parotid gland radioiodine content. Nuclear Medicine Communications, 35(11), 1127-31.

Hong, D. S., DuBois, S. G., Kummar, S., Farago, A. F., Albert, C. M., Rohrberg, K. S., van Tilburg, C. M., Nagasubramanian, R., ... Drilon, A. (2020). Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. The Lancet. Oncology, 21(4), 531-540.

Hotomi, M., Sugitani, I., Toda, K., Kawabata, K., & Fujimoto, Y. (2012). A novel definition of extrathyroidal invasion for patients with papillary thyroid carcinoma for predicting prognosis. World Journal of Surgery, 36(6), 1231-40.

Hundahl, S. A., Fleming, I. D., Fremgen, A. M., & Menck, H. R. (1998). A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer, 83(12), 2638-48.

Hysek, M., Paulsson, J. O., Jatta, K., Shabo, I., Stenman, A., Höög, A., Larsson, C., Zedenius, J., & Juhlin, C. C. (2019). Clinical Routine TERT Promoter Mutational Screening of Follicular Thyroid Tumors of Uncertain Malignant Potential (FT-UMPs): A Useful Predictor of Metastatic Disease. Cancers, 11(10)

Ito, M., Yamashita, S., Ashizawa, K., Hara, T., Namba, H., Hoshi, M., Shibata, Y., Sekine, I., ... Nagataki, S. (1996). Histopathological characteristics of childhood thyroid cancer in Gomel, Belarus. International Journal of Cancer, 65(1), 29-33.

Ito, Y., Hirokawa, M., Hayashi, T., Kihara, M., Onoda, N., Miya, A., & Miyauchi, A. (2022). Clinical outcomes of follicular tumor of uncertain malignant potential of the thyroid: real-world data. Endocrine Journal, 69(7), 757-761.

Ito, Y., Hirokawa, M., Masuoka, H., Yabuta, T., Kihara, M., Higashiyama, T., Takamura, Y., Kobayashi, K., ... Miyauchi, A. (2013). Prognostic factors of minimally invasive follicular thyroid carcinoma: extensive vascular invasion significantly affects patient prognosis. Endocrine Journal, 60(5), 637-42.

Ito, Y., Miyauchi, A., Kudo, T., Oda, H., Yamamoto, M., Sasai, H., Masuoka, H., Fukushima, M., ... Miya, A. (2018). Trends in the Implementation of Active Surveillance for Low-Risk Papillary Thyroid Microcarcinomas at Kuma Hospital: Gradual Increase and Heterogeneity in the Acceptance of This New Management Option. Thyroid, 28(4), 488-495.

Jacobsen, A. B., Grøholt, K. K., Lorntzsen, B., Osnes, T. A., Falk, R. S., & Sigstad, E. (2017). Anaplastic thyroid cancer and hyperfractionated accelerated radiotherapy (HART) with and without surgery. European Archives of Oto-Rhino-Laryngology, 274(12), 4203-4209.

Jung, K. Y., Kim, S. M., Yoo, W. S., Kim, B. W., Lee, Y. S., Kim, K. W., Lee, K. E., Jeong, J. J., ... Chang, H. S. (2016). Postoperative biochemical remission of serum calcitonin is the best predictive factor for recurrence-free survival of medullary thyroid cancer: a large-scale retrospective analysis over 30 years. Clinical Endocrinology, 84(4), 587-97.

Kamani, T., Charkhchi, P., Zahedi, A., & Akbari, M. R. (2022). Genetic susceptibility to hereditary non-medullary thyroid cancer. Hereditary Cancer in Clinical Practice, 20(1), 9.

Kawada, K., Kitagawa, K., Kamei, S., Inada, M., Mitsuma, A., Sawaki, M., Kikumori, T., Fujimoto, Y., ... Ando, Y. (2010). The feasibility study of docetaxel in patients with anaplastic thyroid cancer. Japanese Journal of Clinical Oncology, 40(6), 596-9.

Kebebew, E., Ituarte, P. H., Siperstein, A. E., Duh, Q. Y., & Clark, O. H. (2000). Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer, 88(5), 1139-48.

Khan Bhettani, M., Rehman, M., Ahmed, M., Altaf, H. N., Choudry, U. K., & Khan, K. H. (2019). Role of pre-operative vitamin D supplementation to reduce post-thyroidectomy hypocalcemia; Cohort study. International journal of surgery, 71, 85-90.

Kiernan, C. M., Thomas, G., Patel, A., Fan, R., Ye, F., Willmon, P. A., & Solórzano, C. C. (2023). Does the Use of Probe-based Near-infrared Autofluorescence Parathyroid Detection Benefit Parathyroidectomy?: A Randomized Single-center Clinical Trial. Annals of Surgery, 278(4), 549-558.

Kim, J. H., & Leeper, R. D. (1987). Treatment of locally advanced thyroid carcinoma with combination doxorubicin and radiation therapy. Cancer, 60(10), 2372-5.

Klubo-Gwiezdzinska, J., Van Nostrand, D., Atkins, F., Burman, K., Jonklaas, J., Mete, M., & Wartofsky, L. (2011). Efficacy of dosimetric versus empiric prescribed activity of 131I for therapy of differentiated thyroid cancer. Journal of Clinical Endocrinology and Metabolism, 96(10), 3217-25.

Kobayashi, T., Asakawa, H., Umeshita, K., Takeda, T., Maruyama, H., Matsuzuka, F., & Monden, M. (1996). Treatment of 37 patients with anaplastic carcinoma of the thyroid. Head and Neck, 18(1), 36-41.

Kowalik, A., ... Kowalska, A. (2019). Current Knowledge of Germline Genetic Risk Factors for the Development of Non-Medullary Thyroid Cancer. Genes, 10(7), 482.

Kulkarni, K., Van Nostrand, D., Atkins, F., Aiken, M., Burman, K., & Wartofsky, L. (2006). The relative frequency in which empiric dosages of radioiodine would potentially overtreat or undertreat patients who have metastatic well-differentiated thyroid cancer. Thyroid, 16(10), 1019-23.

Kusakabe, K., Yokoyama, K., Ito, K., Shibuya, H., Kinuya, S., Ito, M., Higashi, T., Togawa, T., ... Yamamoto, A. (2012). Thyroid remnant ablation using 1,110 MBq of I-131 after total thyroidectomy: regulatory considerations on release of patients after unsealed radioiodine therapy. Annals of Nuclear Medicine, 26(4), 370-8.

Lamartina, L., Grani, G., Durante, C., Borget, I., Filetti, S., & Schlumberger, M. (2018). Follow-up of differentiated thyroid cancer - what should (and what should not) be done. Nature reviews. Endocrinology, 14(9), 538-551.

Lambrecht, M., Eekers, D. B. P., Alapetite, C., Burnet, N. G., Calugaru, V., Coremans, I. E. M., Fossati, P., Høyer, M., ... Troost, E. G. C. (2018). Radiation dose constraints for organs at risk in neuro-oncology; the European Particle Therapy Network consensus. Radiotherapy and Oncology, 128(1), 26-36.

Larsen, I. K. (2022). Cancer in Norway 2021: Cancer incidence, mortality, survival and prevalence in Norway. Cancer Registry of Norway.

Larsen, I. K. (2023). Cancer in Norway 2022: Cancer incidence, mortality, survival and prevalence in Norway. Cancer Registry of Norway.

Layfield, L. J., Abrams, J., Cochand-Priollet, B., Evans, D., Gharib, H., Greenspan, F., Henry, M., LiVolsi, V., ... Wells, S. A. (2008). Post-thyroid FNA testing and treatment options: a synopsis of the National Cancer Institute Thyroid Fine Needle Aspiration State of the Science Conference. Diagnostic Cytopathology, 36(6), 442-8.

Leboulleux, S., Bournaud, C., Chougnet, C. N., Zerdoud, S., Al Ghuzlan, A., Catargi, B., Do Cao, C., Kelly, A., ... Borget, I. (2022). Thyroidectomy without Radioiodine in Patients with Low-Risk Thyroid Cancer. New England Journal of Medicine, 386(10), 923-932.

Lee, J., Yun, M. J., Nam, K. H., Chung, W. Y., Soh, E. Y., & Park, C. S. (2010). Quality of life and effectiveness comparisons of thyroxine withdrawal, triiodothyronine withdrawal, and recombinant thyroid-stimulating hormone administration for low-dose radioiodine remnant ablation of differentiated thyroid carcinoma. Thyroid, 20(2), 173-9.

Lee, J. J., Chung, J. K., Kim, S. E., Kang, W. J., Park, D. J., Lee, D. S., Cho, B. Y., & Lee, M. C. (2008). Maximal safe dose of I-131 after failure of standard fixed dose therapy in patients with differentiated thyroid carcinoma. Annals of Nuclear Medicine, 22(9), 727-34.

Levendag, P. C., De Porre, P. M., & van Putten, W. L. (1993). Anaplastic carcinoma of the thyroid gland treated by radiation therapy. International Journal of Radiation Oncology, Biology, Physics, 26(1), 125-8.

Lin, J. F., Rodriguez Schaap, P. M., Metman, M. J. H., Nieveen van Dijkum, E. J. M., Dickhoff, C., Links, T. P., Kruijff, S., & Engelsman, A. F. (2023). Thyroid Lobectomy for Low-Risk 1-4 CM Papillary Thyroid Cancer is not Associated with Increased Recurrence Rates in the Dutch Population with a Restricted Diagnostic Work-Up. World Journal of Surgery, 47(5), 1211-1218.

Locati, L., Cavalieri, S., Dal Maso, L., Busco, S., Anderson, L. A., Botta, L., Bento, M. J., Carulla, M., ... Trama, A. (2020). Rare thyroid malignancies in Europe: Data from the information network on rare cancers in Europe (RARECAREnet). Oral Oncology, 108, 104766.

Lorntzsen, B., Brøndbo, K., & Osnes, T. (2020). From the clavicle to the windpipe: Tracheal window resections reconstructed with calcifying periosteum in thyroid cancer. Laryngoscope investigative otolaryngology, 5(5), 961-968.

Lorntzsen, B., Jacobsen, A. B., GrØholt, K. K., Sigstad, E., & Osnes, T. (2020). Survival and Surgical Complications in Anaplastic Thyroid Cancer Patients After Completed Multimodal Treatment. Anticancer Research, 40(12), 6979-6985.

Lundh, C., Nordén, M. M., Nilsson, M., & Forssell-Aronsson, E. (2007). Reduced iodide transport (stunning) and DNA synthesis in thyrocytes exposed to low absorbed doses from 131I in vitro. Journal of Nuclear Medicine, 48(3), 481-6.

Lykke, E., Christensen, A., Juhl, K., Feldt-Rasmussen, U., Friberg Hitz, M., Svenningsen Sjöstedt, S. M., Holst Hahn, C., Kraik Svensson, D. M., ... von Buchwald, C. (2023). Effect of near infrared autofluorescence guided total thyroidectomy on postoperative hypoparathyroidism: a randomized clinical trial. European Archives of Oto-Rhino-Laryngology, 280(5), 2593-2603.

Machens, A., & Dralle, H. (2010). Biomarker-based risk stratification for previously untreated medullary thyroid cancer. Journal of Clinical Endocrinology and Metabolism, 95(6), 2655-63.

Machens, A., & Dralle, H. (2016). Surgical cure rates of sporadic medullary thyroid cancer in the era of calcitonin screening. European journal of endocrinology, 175(3), 219-28.

Machens, A., Schneyer, U., Holzhausen, H. J., & Dralle, H. (2005). Prospects of remission in medullary thyroid carcinoma according to basal calcitonin level. Journal of Clinical Endocrinology and Metabolism, 90(4), 2029-34.

Mauri, G., Hegedüs, L., Bandula, S., Cazzato, R. L., Czarniecka, A., Dudeck, O., Fugazzola, L., Netea-Maier, R., ... Papini, E. (2021). European Thyroid Association and Cardiovascular and Interventional Radiological Society of Europe 2021 Clinical Practice Guideline for the Use of Minimally Invasive Treatments in Malignant Thyroid Lesions. European thyroid journal, 10(3), 185-197.

Maxon, H. R. ,. 3., Englaro, E. E., Thomas, S. R., Hertzberg, V. S., Hinnefeld, J. D., Chen, L. S., Smith, H., Cummings, D., & Aden, M. D. (1992). Radioiodine-131 therapy for well-differentiated thyroid cancer--a quantitative radiation dosimetric approach: outcome and validation in 85 patients. Journal of Nuclear Medicine, 33(6), 1132-6.

Maxon, H. R., Thomas, S. R., Hertzberg, V. S., Kereiakes, J. G., Chen, I. W., Sperling, M. I., & Saenger, E. L. (1983). Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. New England Journal of Medicine, 309(16), 937-41.

McCaffrey, T. V., Bergstralh, E. J., & Hay, I. D. (1994). Locally invasive papillary thyroid carcinoma: 1940-1990. Head and Neck, 16(2), 165-72.

Meijer, J. A., le Cessie, S., van den Hout, W. B., Kievit, J., Schoones, J. W., Romijn, J. A., & Smit, J. W. (2010). Calcitonin and carcinoembryonic antigen doubling times as prognostic factors in medullary thyroid carcinoma: a structured meta-analysis. Clinical Endocrinology, 72(4), 534-42.

Miasaki, F. Y., Fuziwara, C. S., Carvalho, G. A., & Kimura, E. T. (2020). Genetic Mutations and Variants in the Susceptibility of Familial Non-Medullary Thyroid Cancer. Genes, 11(11)

Moley, J. F. (2010). Medullary thyroid carcinoma: management of lymph node metastases. Journal of the National Comprehensive Cancer Network : JNCCN, 8(5), 549-56.

Moon, S., Song, Y. S., Kim, Y. A., Lim, J. A., Cho, S. W., Moon, J. H., Hahn, S., Park, D. J., & Park, Y. J. (2017). Effects of Coexistent BRAF(V600E) and TERT Promoter Mutations on Poor Clinical Outcomes in Papillary Thyroid Cancer: A Meta-Analysis. Thyroid, 27(5), 651-660.

Mu, C., Ming, X., Tian, Y., Liu, Y., Yao, M., Ni, Y., Liu, Y., & Li, Z. (2022). Mapping global epidemiology of thyroid nodules among general population: A systematic review and meta-analysis. Frontiers in Oncology, 12, 1029926.

Mulligan, L. M., Kwok, J. B., Healey, C. S., Elsdon, M. J., Eng, C., Gardner, E., Love, D. R., Mole, S. E., ... et al. (1993). Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature, 363(6428), 458-60.

Najdawi, F., Ahmadi, S., Capelletti, M., Dong, F., Chau, N. G., & Barletta, J. A. (2021). Evaluation of grade in a genotyped cohort of sporadic medullary thyroid carcinomas. Histopathology, 79(3), 427-436.

Nikiforov, Y. E., & Nikiforova, M. N. (2011). Molecular genetics and diagnosis of thyroid cancer. Nature reviews. Endocrinology, 7(10), 569-80.

Nishida, T., Nakao, K., Hamaji, M., Kamiike, W., Kurozumi, K., & Matsuda, H. (1997). Preservation of recurrent laryngeal nerve invaded by differentiated thyroid cancer. Annals of Surgery, 226(1), 85-91.

Opsahl, E. M., Akslen, L. A., Schlichting, E., Aas, T., Brauckhoff, K., Hagen, A. I., Rosenlund, A. F., Sigstad, E., ... Bjøro, T. (2019). The Role of Calcitonin in Predicting the Extent of Surgery in Medullary Thyroid Carcinoma: A Nationwide Population-Based Study in Norway. European thyroid journal, 8(3), 159-166.

Opsahl, E. M., Akslen, L. A., Schlichting, E., Aas, T., Brauckhoff, K., Hagen, A. I., Rosenlund, A. F., Sigstad, E., ... Bjøro, T. (2019). Trends in Diagnostics, Surgical Treatment, and Prognostic Factors for Outcomes in Medullary Thyroid Carcinoma in Norway: A Nationwide Population-Based Study. European thyroid journal, 8(1), 31-40.

Orloff, L. A., Noel, J. E., Stack, B. C. ,. J., Russell, M. D., Angelos, P., Baek, J. H., Brumund, K. T., Chiang, F. Y., ... Randolph, G. W. (2022). Radiofrequency ablation and related ultrasound-guided ablation technologies for treatment of benign and malignant thyroid disease: An international multidisciplinary consensus statement of the American Head and Neck Society Endocrine Surgery Section with the Asia Pacific Society of Thyroid Surgery, Associazione Medici Endocrinologi, British Association of Endocrine and Thyroid Surgeons, European Thyroid Association, Italian Society of Endocrine Surgery Units, Korean Society of Thyroid Radiology, Latin American Thyroid Society, and Thyroid Nodules Therapies Association. Head and Neck, 44(3), 633-660.

Orois, A., Mora, M., Halperin, I., & Oriola, J. (2021). Familial non medullary thyroid carcinoma: Beyond the syndromic forms. Endocrinologia, diabetes y nutricion, 68(4), 260-269.

Osamura, R. Y., Yasuda, O., Kawakami, T., Itoh, Y., Inada, K., & Kakudo, K. (1997). Immunoelectron microscopic demonstration of regulated pathway for calcitonin and constitutive pathway for carcinoembryonic antigen in the same cells of human medullary carcinomas of thyroid glands. Modern Pathology, 10(1), 7-11.

Park, S., Kim, W. G., Song, E., Oh, H. S., Kim, M., Kwon, H., Jeon, M. J., Kim, T. Y., ... Kim, W. B. (2017). Dynamic Risk Stratification for Predicting Recurrence in Patients with Differentiated Thyroid Cancer Treated Without Radioactive Iodine Remnant Ablation Therapy. Thyroid, 27(4), 524-530.

Park, S. Y., Kim, H. I., Kim, J. H., Kim, J. S., Oh, Y. L., Kim, S. W., Chung, J. H., Jang, H. W., & Kim, T. H. (2018). Prognostic significance of gross extrathyroidal extension invading only strap muscles in differentiated thyroid carcinoma. The British journal of surgery, 105(9), 1155-1162.

Pelizzo, M. R., Boschin, I. M., Bernante, P., Toniato, A., Piotto, A., Pagetta, C., Nibale, O., Rampin, L., ... Rubello, D. (2007). Natural history, diagnosis, treatment and outcome of medullary thyroid cancer: 37 years experience on 157 patients. European Journal of Surgical Oncology, 33(4), 493-7.

Perros, P., Boelaert, K., Colley, S., Evans, C., Evans, R. M., Gerrard Ba, G., Gilbert, J., Harrison, B., ... Williams, G. R. (2014). Guidelines for the management of thyroid cancer. Clinical Endocrinology, 81 Suppl 1, 1-122.

Piek, M. W., de Boer, J. P., Vriens, M. R., van Leeuwaarde, R. S., Stokkel, M., Hartemink, K. J., van Duijnhoven, F., Kessels, R., & van der Ploeg, I. M. C. (2021). Retrospective Analyses of (18)FDG-PET/CT Thyroid Incidentaloma in Adults: Incidence, Treatment, and Outcome in a Tertiary Cancer Referral Center. Thyroid, 31(11), 1715-1722.

Pierie, J. P., Muzikansky, A., Gaz, R. D., Faquin, W. C., & Ott, M. J. (2002). The effect of surgery and radiotherapy on outcome of anaplastic thyroid carcinoma. Annals of Surgical Oncology, 9(1), 57-64.

Prasongsook, N., Kumar, A., Chintakuntlawar, A. V., Foote, R. L., Kasperbauer, J., Molina, J., Garces, Y., Ma, D., ... Bible, K. C. (2017). Survival in Response to Multimodal Therapy in Anaplastic Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 102(12), 4506-4514.

Randle, R. W., Balentine, C. J., Leverson, G. E., Havlena, J. A., Sippel, R. S., Schneider, D. F., & Pitt, S. C. (2017). Trends in the presentation, treatment, and survival of patients with medullary thyroid cancer over the past 30 years. Surgery, 161(1), 137-146.

Randolph, G. W., Cernea, C. R., Dralle, H., Dionigi, G., Alesina, P. F., Mihai, R., Finck, C., Lombardi, D., ... Hisham, A. N. (2013). External branch of the superior laryngeal nerve monitoring during thyroid and parathyroid surgery: International Neural Monitoring Study Group standards guideline statement. Laryngoscope, 123(Suppl 4), S1-14.

Randolph, G. W., & Kamani, D. (2006). The importance of preoperative laryngoscopy in patients undergoing thyroidectomy: voice, vocal cord function, and the preoperative detection of invasive thyroid malignancy. Surgery, 139(3), 357-62.

Raue, F., & Frank-Raue, K. (2018). Update on Multiple Endocrine Neoplasia Type 2: Focus on Medullary Thyroid Carcinoma. Journal of the Endocrine Society, 2(8), 933-943.

Reinke, R., Londero, S. C., Almquist, M., Rejnmark, L., & Rolighed, L. (2023). Total thyroidectomy: reduction in postoperative hypoparathyroidism. Endocrine connections, 12(9)

Rohmer, V., Vidal-Trecan, G., Bourdelot, A., Niccoli, P., Murat, A., Wemeau, J. L., Borson-Chazot, F., Schvartz, C., ... Baudin, E. (2011). Prognostic factors of disease-free survival after thyroidectomy in 170 young patients with a RET germline mutation: a multicenter study of the Groupe Francais d'Etude des Tumeurs Endocrines. Journal of Clinical Endocrinology and Metabolism, 96(3), E509-18.

Rosai, J., DeLellis, R. A., Carcangiu, M. L., Frable, W. J., Tallini, G. (2014). Tumors of the thyroid and parathyroid glands (AFIP Atlas of Tumor Pathology Series 4). Rockville, MD: American Registry of Pathology.

Royal College of Pathologists of Australasia (2022). Thyroid Cancer Structured Reporting Protocol (2 utg.) Surry Hills, NSW: RCPA. Hentet fra https://www.rcpa.edu.au/Library/Practising-Pathology/Structured-Pathology-Reporting-of-Cancer/Cancer-Protocols/Head-Neck-Endocrine/Protocol-thyroid-cancer.aspx

Rubin, S. J., Park, J. H., Pearce, E. N., Holick, M. F., McAneny, D., & Noordzij, J. P. (2020). Vitamin D Status as a Predictor of Postoperative Hypocalcemia after Thyroidectomy. Otolaryngology--head and neck surgery, 163(3), 501-507.

Salem, F. A., Bergenfelz, A., Nordenström, E., & Almquist, M. (2021). Central lymph node dissection and permanent hypoparathyroidism after total thyroidectomy for papillary thyroid cancer: population-based study. British Journal of Surgery, 108(6), 684-690.

Salvatore, D., Santoro, M., & Schlumberger, M. (2021). The importance of the RET gene in thyroid cancer and therapeutic implications. Nature reviews. Endocrinology, 17(5), 296-306.

Schlumberger, M., Tahara, M., Wirth, L. J., Robinson, B., Brose, M. S., Elisei, R., Habra, M. A., Newbold, K., ... Sherman, S. I. (2015). Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. New England Journal of Medicine, 372(7), 621-30.

Schneider, R., Randolph, G. W., Dionigi, G., Wu, C. W., Barczynski, M., Chiang, F. Y., Al-Quaryshi, Z., Angelos, P., ... Dralle, H. (2018). International neural monitoring study group guideline 2018 part I: Staging bilateral thyroid surgery with monitoring loss of signal. Laryngoscope, 128(Suppl 3), S1-s17.

Schwartz, D. L., Lobo, M. J., Ang, K. K., Morrison, W. H., Rosenthal, D. I., Ahamad, A., Evans, D. B., Clayman, G., ... Garden, A. S. (2009). Postoperative external beam radiotherapy for differentiated thyroid cancer: outcomes and morbidity with conformal treatment. International Journal of Radiation Oncology, Biology, Physics, 74(4), 1083-91.

Sherman, E. J., Lim, S. H., Ho, A. L., Ghossein, R. A., Fury, M. G., Shaha, A. R., Rivera, M., Lin, O., ... Pfister, D. G. (2011). Concurrent doxorubicin and radiotherapy for anaplastic thyroid cancer: a critical re-evaluation including uniform pathologic review. Radiotherapy and Oncology, 101(3), 425-30.

Smallridge, R. C., Ain, K. B., Asa, S. L., Bible, K. C., Brierley, J. D., Burman, K. D., Kebebew, E., Lee, N. Y., ... Tuttle, R. M. (2012). American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid, 22(11), 1104-39.

Song, E., Lee, Y. M., Oh, H. S., Jeon, M. J., Song, D. E., Kim, T. Y., Kim, W. B., Shong, Y. K., ... Kim, W. G. (2019). A Relook at the T Stage of Differentiated Thyroid Carcinoma with a Focus on Gross Extrathyroidal Extension. Thyroid, 29(2), 202-208.

Srivastava, A., Giangiobbe, S., Skopelitou, D., Miao, B., Paramasivam, N., Diquigiovanni, C., Bonora, E., Hemminki, K., ... Bandapalli, O. R. (2021). Whole Genome Sequencing Prioritizes CHEK2, EWSR1, and TIAM1 as Possible Predisposition Genes for Familial Non-Medullary Thyroid Cancer. Frontiers in Endocrinology, 12, 600682.

Stewart, M. W. (2022). Doctor I Have an Iodine Allergy. Ophthalmology and therapy, 11(3), 931-938.

Subbiah, V., Hu, M. I., Wirth, L. J., Schuler, M., Mansfield, A. S., Curigliano, G., Brose, M. S., Zhu, V. W., ... Taylor, M. H. (2021). Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study. The lancet. Diabetes & endocrinology, 9(8), 491-501.

Subbiah, V., Kreitman, R. J., Wainberg, Z. A., Cho, J. Y., Schellens, J. H. M., Soria, J. C., Wen, P. Y., Zielinski, C., ... Keam, B. (2018). Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer. Journal of Clinical Oncology, 36(1), 7-13.

Subbiah, V., Kreitman, R. J., Wainberg, Z. A., Cho, J. Y., Schellens, J. H. M., Soria, J. C., Wen, P. Y., Zielinski, C. C., ... Keam, B. (2022). Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study. Annals of Oncology, 33(4), 406-415.

Sugitani, I., Onoda, N., Ito, K. I., & Suzuki, S. (2018). Management of Anaplastic Thyroid Carcinoma: the Fruits from the ATC Research Consortium of Japan. Journal of Nippon Medical School = Nippon Ika Daigaku zasshi, 85(1), 18-27.

Swaak-Kragten, A. T., de Wilt, J. H., Schmitz, P. I., Bontenbal, M., & Levendag, P. C. (2009). Multimodality treatment for anaplastic thyroid carcinoma--treatment outcome in 75 patients. Radiotherapy and Oncology, 92(1), 100-4.

Tahara, M., Kiyota, N., Yamazaki, T., Chayahara, N., Nakano, K., Inagaki, L., Toda, K., Enokida, T., ... Takahashi, S. (2017). Lenvatinib for Anaplastic Thyroid Cancer. Frontiers in Oncology, 7, 25.

Tennvall, J., Lundell, G., Wahlberg, P., Bergenfelz, A., Grimelius, L., Akerman, M., Hjelm Skog, A. L., & Wallin, G. (2002). Anaplastic thyroid carcinoma: three protocols combining doxorubicin, hyperfractionated radiotherapy and surgery. British Journal of Cancer, 86(12), 1848-53.

Terezakis, S. A., Lee, K. S., Ghossein, R. A., Rivera, M., Tuttle, R. M., Wolden, S. L., Zelefsky, M. J., Wong, R. J., ... Lee, N. Y. (2009). Role of external beam radiotherapy in patients with advanced or recurrent nonanaplastic thyroid cancer: Memorial Sloan-kettering Cancer Center experience. International Journal of Radiation Oncology, Biology, Physics, 73(3), 795-801.

Treglia, G., Castaldi, P., Villani, M. F., Perotti, G., de Waure, C., Filice, A., Ambrosini, V., Cremonini, N., ... Rufini, V. (2012). Comparison of 18F-DOPA, 18F-FDG and 68Ga-somatostatin analogue PET/CT in patients with recurrent medullary thyroid carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 39(4), 569-80.

Treglia, G., Rufini, V., Piccardo, A., & Imperiale, A. (2023). Update on Management of Medullary Thyroid Carcinoma: Focus on Nuclear Medicine. Seminars in Nuclear Medicine, 53(4), 481-489.

Troch, M., Koperek, O., Scheuba, C., Dieckmann, K., Hoffmann, M., Niederle, B., & Raderer, M. (2010). High efficacy of concomitant treatment of undifferentiated (anaplastic) thyroid cancer with radiation and docetaxel. Journal of Clinical Endocrinology and Metabolism, 95(9), E54-7.

Tuttle, R. M., Leboeuf, R., Robbins, R. J., Qualey, R., Pentlow, K., Larson, S. M., & Chan, C. Y. (2006). Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer. Journal of Nuclear Medicine, 47(10), 1587-91.

Tuttle, R. M., Li, D., & Ridouani, F. (2023). Percutaneous ablation of low-risk papillary thyroid cancer. Endocrine-Related Cancer, 30(3)

Tuttle, R. M., Tala, H., Shah, J., Leboeuf, R., Ghossein, R., Gonen, M., Brokhin, M., Omry, G., ... Shaha, A. (2010). Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid, 20(12), 1341-9.

van Beek, D. J., Almquist, M., Bergenfelz, A. O., Musholt, T. J., & Nordenström, E. (2021). Complications after medullary thyroid carcinoma surgery: multicentre study of the SQRTPA and EUROCRINE® databases. British Journal of Surgery, 108(6), 691-701.

van der Molen, A. J., Thomsen, H. S., & Morcos, S. K. (2004). Effect of iodinated contrast media on thyroid function in adults. European Radiology, 14(5), 902-7.

van Heerden, J. A., Grant, C. S., Gharib, H., Hay, I. D., & Ilstrup, D. M. (1990). Long-term course of patients with persistent hypercalcitoninemia after apparent curative primary surgery for medullary thyroid carcinoma. Annals of Surgery, 212(4), 395-400; discussion 400-1.

Verbeek, H. H., Plukker, J. T., Koopmans, K. P., de Groot, J. W., Hofstra, R. M., Muller Kobold, A. C., van der Horst-Schrivers, A. N., Brouwers, A. H., & Links, T. P. (2012). Clinical relevance of 18F-FDG PET and 18F-DOPA PET in recurrent medullary thyroid carcinoma. Journal of Nuclear Medicine, 53(12), 1863-71.

Vitale, G., Fonderico, F., Martignetti, A., Caraglia, M., Ciccarelli, A., Nuzzo, V., Abbruzzese, A., & Lupoli, G. (2001). Pamidronate improves the quality of life and induces clinical remission of bone metastases in patients with thyroid cancer. British Journal of Cancer, 84(12), 1586-90.

Volante, M., Lam, A. K., Papotti, M., & Tallini, G. (2021). Molecular Pathology of Poorly Differentiated and Anaplastic Thyroid Cancer: What Do Pathologists Need to Know?. Endocrine Pathology, 32(1), 63-76.

Vuong, H. G., Altibi, A. M. A., Duong, U. N. P., & Hassell, L. (2017). Prognostic implication of BRAF and TERT promoter mutation combination in papillary thyroid carcinoma-A meta-analysis. Clinical Endocrinology, 87(5), 411-417.

Wada, N., Nakayama, H., Masudo, Y., Suganuma, N., & Rino, Y. (2006). Clinical outcome of different modes of resection in papillary thyroid carcinomas with laryngotracheal invasion. Langenbeck's archives of surgery, 391(6), 545-9.

Walrand, S., Hesse, M., & Jamar, F. (2015). Statistical and radiobiological analysis of the so-called thyroid stunning. EJNMMI research, 5(1), 67.

Wang, J., Guli, Q. R., Ming, X. C., Zhou, H. T., Cui, Y. J., Jiang, Y. F., Zhang, D., & Liu, Y. (2018). Primary mucinous carcinoma of thyroid gland with prominent signet-ring-cell differentiation: a case report and review of the literature. OncoTargets and Therapy, 11, 1521-1528.

Wang, J. R., Zafereo, M. E., Dadu, R., Ferrarotto, R., Busaidy, N. L., Lu, C., Ahmed, S., Gule-Monroe, M. K., ... Cabanillas, M. E. (2019). Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in BRAF(V600E)-Mutated Anaplastic Thyroid Carcinoma. Thyroid, 29(8), 1036-1043.

Wang, Y., Tsang, R., Asa, S., Dickson, B., Arenovich, T., & Brierley, J. (2006). Clinical outcome of anaplastic thyroid carcinoma treated with radiotherapy of once- and twice-daily fractionation regimens. Cancer, 107(8), 1786-92.

Wells, S. A. ,. J., Asa, S. L., Dralle, H., Elisei, R., Evans, D. B., Gagel, R. F., Lee, N., Machens, A., ... Waguespack, S. G. (2015). Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid, 25(6), 567-610.

Wells, S. A. ,. J., Robinson, B. G., Gagel, R. F., Dralle, H., Fagin, J. A., Santoro, M., Baudin, E., Elisei, R., ... Schlumberger, M. J. (2012). Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. Journal of Clinical Oncology, 30(2), 134-41.

Wenig, B. M., Adair, C. F., & Heffess, C. S. (1995). Primary mucoepidermoid carcinoma of the thyroid gland: a report of six cases and a review of the literature of a follicular epithelial-derived tumor. Human Pathology, 26(10), 1099-108.

WHO Classification of Tumours Editorial Board (2022). Endocrine Tumours [Beta version ahead of print] (5 utg.) Lyon: International Agency for Research on Cancer. Hentet fra https://tumourclassification.iarc.who.int/

Wirth, L. J., Brose, M. S., Subbiah, V., Worden, F., Solomon, B., Robinson, B., Hadoux, J., Tomasini, P., ... Cassier, P. A. (2024). Durability of Response With Selpercatinib in Patients With RET-Activated Thyroid Cancer: Long-Term Safety and Efficacy From LIBRETTO-001. Journal of Clinical Oncology, 42(27), 3187-3195.

Wirth, L. J., Sherman, E., Robinson, B., Solomon, B., Kang, H., Lorch, J., Worden, F., Brose, M., ... Cabanillas, M. E. (2020). Efficacy of Selpercatinib in RET-Altered Thyroid Cancers. New England Journal of Medicine, 383(9), 825-835.

Wolf, H. W., Runkel, N., Limberger, K., & Nebiker, C. A. (2022). Near-infrared autofluorescence of the parathyroid glands during thyroidectomy for the prevention of hypoparathyroidism: a prospective randomized clinical trial. Langenbeck's archives of surgery, 407(7), 3031-3038.

Workman, A. D., Soylu, S., Kamani, D., Nourmahnad, A., Kyriazidis, N., Saade, R., Ren, Y., Wirth, L., ... Randolph, G. W. (2021). Limitations of preoperative cytology for medullary thyroid cancer: Proposal for improved preoperative diagnosis for optimal initial medullary thyroid carcinoma specific surgery. Head and Neck, 43(3), 920-927.

Wu, C. W., Dionigi, G., Barczynski, M., Chiang, F. Y., Dralle, H., Schneider, R., Al-Quaryshi, Z., Angelos, P., ... Randolph, G. W. (2018). International neuromonitoring study group guidelines 2018: Part II: Optimal recurrent laryngeal nerve management for invasive thyroid cancer-incorporation of surgical, laryngeal, and neural electrophysiologic data. Laryngoscope, 128(Suppl 3), S18-s27.

Xu, B., Fuchs, T., Dogan, S., Landa, I., Katabi, N., Fagin, J. A., Tuttle, R. M., Sherman, E., ... Ghossein, R. (2020). Dissecting Anaplastic Thyroid Carcinoma: A Comprehensive Clinical, Histologic, Immunophenotypic, and Molecular Study of 360 Cases. Thyroid, 30(10), 1505-1517.

Xu, B., Wang, L., Tuttle, R. M., Ganly, I., & Ghossein, R. (2015). Prognostic impact of extent of vascular invasion in low-grade encapsulated follicular cell-derived thyroid carcinomas: a clinicopathologic study of 276 cases. Human Pathology, 46(12), 1789-98.

Yadav, M., Agrawal, V., Pani, K. C., Verma, R., Jaiswal, S., Mishra, A., & Pandey, R. (2018). C-cell hyperplasia in sporadic and familial medullary thyroid carcinoma. Indian Journal of Pathology and Microbiology, 61(4), 485-488.

Yoon, J. K., Lee, J., Kim, E. K., Yoon, J. H., Park, V. Y., Han, K., & Kwak, J. Y. (2020). Strap muscle invasion in differentiated thyroid cancer does not impact disease-specific survival: a population-based study. Scientific Reports, 10(1), 18248.

Zhuang, S. M., Xie, L. E., Pang, F., Zhong, Q. Y., Sun, X. M., Wen, W. P., & Liu, T. R. (2021). Role of primary tumor resection in patients with metastatic medullary thyroid cancer who have unresectable distant metastases. Head and Neck, 43(11), 3386-3392.